Regular articleImmunopathology and infectious diseaseThe Melanocortin Agonist AP214 Exerts Anti-Inflammatory and Proresolving Properties
Immunopathology and infectious disease
Under an Elsevier user license
open archive
Cited by (0)
Supported by a collaborative project between Action Pharma A/S and the William Harvey Research Foundation. This work forms part of the research themes contributing to the translational research portfolio of Barts and the London Cardiovascular Biomedical Research Unit, which is supported and funded by the National Institute for Health Research.
Disclosures: S.N. is cofounder and CEO of Action Pharma A/S (currently COO), and T.E.N.J. is cofounder of Action Pharma A/S.
Copyright © 2011 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.